NASCENT BIOTECH, INC. (OTCMKTS:NBIO) Files An 8-K Regulation FD DisclosureITEM 7.01 FD Disclosure
(a) Nascent Biotech, Inc. (the “Company”) issued a press release on January 25, 2018, a copy of which is attached hereto as an exhibit.
(b) The information contained in this Section 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.
ITEM 8.01 Other Events
The Company has been approved to begin trading on the OTCQB effective January 25, 2018. The Company was previously traded on the OTC Pink market.
ITEM 9.01 Financial Statements and Exhibits
|
Exhibit No. |
Description of Exhibit |
|
99(i)* |
January 25, 2018 Press Release |
__________
*filed herewith
Nascent Biotech Inc. ExhibitEX-99.1 2 nbio_ex991.htm PRESS RELEASE nbio_ex991.htmEXHIBIT 99.1 Press Release NASCENT BIOTECH UPLISTS TO THE OTC QB MARKETS Vero Beach,…To view the full exhibit click here
About NASCENT BIOTECH, INC. (OTCMKTS:NBIO)
Nascent Biotech Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The Company is engaged in the research and development of the antibodies for control of brain and pancreatic cancer in humans. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company owns the license rights to a drug candidate, pritumumab, which it is developing. The Company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. Pritumumab is a monoclonal antibody. The Company has not generated revenues.